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A Potential Role for Auto-Graft Immune Cell Subsets to
Inﬂuence Post-Transplant Outcomes in Multiple
Myeloma
Jennifer H. Cooperrider 1, David Ciarlariello 2, Tiffany Hughes 2,
Nita Williams 2, Craig C. Hofmeister 3, Don M. Benson 3. 1 The
Ohio State University College of Medicine, Columbus, OH;
2 Comprehensive Cancer Center, The Ohio State University,
Columbus, OH; 3Division of Hematology, The Ohio State
University, Columbus, OH
Early lymphocyte recovery is associated with improved
progression free survival (PFS) after autologous stem cell
transplantation in multiple myeloma (MM). In fact, the
number of infused autograft NK cells was found to correlate
directly with early absolute lymphocyte count (ALC) in
retrospective, subset analyses. To assess a potential role for
re-infused lymphocytes in post-transplant outcome, we
characterized stem cell graft lymphocyte subsets in associ-
ation with post-transplant immune reconstitution and sur-
vival in MM. We studied clinical patient outcomes and
performed immunophenotypic analyses on cryopreserved
apheresis samples from 27 MM patients to determine
whether a particular immunophenotypic proﬁle correlated
with early ALC and/or PFS after transplant. We investigated
subsets using markers on NK cells, T cells, and B cells. Out of
the phenotypic analyses performed, the single strong signal
associated with an improved outcome was an inverse cor-
relation between NKG2A expression on cytolytic CD56dim
NK cells and survival (p¼0.011, Spearman’s r¼-0.480). This
suggests that reduced inhibition of NK cells through NKG2A
leads to improved outcomes after ASCT. Interestingly, this
beneﬁcial decrease in NKG2A expression was also correlated
with a trending decrease in pro-inﬂammatory Th1 cells
(p¼0.086, Spearman’s r¼0.336). Although lacking statistical
signiﬁcance in our small sample size, the increased presence
of Th1 pro-inﬂammatory T cells in the stem cell graft
appeared to negatively correlate with PFS (p¼0.109, Spear-
man’s r¼0.136). These data suggest that the presence of a
skewed immune cell phenotype toward amore activating NK
cell proﬁle (decreased inhibition through NKG2A) and away
from a pro-inﬂammatory T cell proﬁle within the stem cell
graft could confer improved PFS. While our data did not
show a correlation between an increased proportion of NK
cells in the graft and survival, they suggest that a less
inhibited NK cell proﬁle could mediate differences in patientFigure 1. Pretransplant MRD predicts outcome of mantle cell lymphoma patients in c
and (b) progression-free survival.outcome after transplant. Further investigation should be
aimed at delineating the role of NKG2A on reconstituting NK
cells following autograft, and the potential efﬁcacy of NKG2A
blockade in immune recovery and tumor surveillance in or-
der to unlock translational avenues to increase survival in the
post-transplant setting.
144
Pretransplant Minimal Residual Disease (MRD) Positivity
Independently Predicts Survival in a Unselected Cohort of
Mantle Cell Lymphoma Undergoing Autologous Stem Cell
Transplantation in Complete Remission
Andrew J. Cowan 1, Philip A. Stevenson 2, Ryan D. Cassaday 3,
Solomon A. Graf 2, Leona Holmberg 1, Jonathan R. Fromm4,
Brian G. Till 1, David Wu4, Thomas Chauncey 5,
Stephen D. Smith 1, Mary Philip 1, Johnnie J. Orozco 6,
Andrei R. Shustov 1, Damian J. Green 6, Edward N. Libby 2,
William Bensinger 1, Mazyar Shadman 7, David G. Maloney 8,
Oliver W. Press 9, Ajay K. Gopal 1. 1 Clinical Research Division,
Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA;
2 Fred Hutchinson Cancer Research Center (FHCRC), Seattle,
WA; 3Department of Medicine, University of Washington,
Seattle, WA; 4Department of Laboratory Medicine, University
of Washington, Seattle, WA; 5Marrow Transplant Unit, VA
Puget Sound Healthcare System (VAPSHCS), Seattle, WA;
6Division of Clinical Research, Fred Hutchinson Cancer
Research Center, Seattle, WA; 7Medicine/Medical Oncology,
University of Washington, Seattle, WA; 8 Clinical Research
Division, Fred Hutchinson Cancer Research Center, Seattle, WA;
9 Clinical Research Division, Fred Hutchinson Cancer Research
Ctr/U. Washington, Seattle, WA
Background: High-dose therapy and autologous stem cell
transplantation (ASCT) is a standard therapy for mantle cell
lymphoma (MCL) patients in ﬁrst remission following in-
duction chemotherapy yet outcomes following this approach
are variable even for patients in complete remission (CR). The
presence of minimal residual disease (MRD) has been shown
to be associated with outcome in other settings, yet limited
data exist on the utility of this measure prior to ASCT. We
hypothesized that evaluation of MRD prior to initiation of
conditioning could stratify CR patients into high or low risk
of relapse and could be used to guide additional post-
transplant therapies.
Methods: Sequential patients with conﬁrmed MCL, age  18
years who underwent ASCT between 1996 and 2011 at the
Fred Hutchinson Cancer Research Center, University ofomplete remission undergoing ASCT. Kaplan-Meier plots for (a) overall survival
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Sound Healthcare System were eligible. Presence of a clonal
IgH rearrangement, t(11;14) by PCR or positive ﬂow cytom-
etry from blood or bone marrow prior to transplant was
scored as MRD positive. MRD along with clinical factors were
evaluated in an adjusted proportional hazards model for
associations with progression-free (PFS) and overall survival
(OS).
Results: Seventy-ﬁve transplanted MCL patients in CR had
pretransplant MRD evaluation performed. The median age
was 58 years (range, 38-71), 59 (78.7%) were men, the me-
dian number of prior regimens was 1 (range 1-4), and the
median MIPI score was 2 (range 0-7). Induction chemo-
therapy consisted of HyperCVAD in 37 (49.3%), CHOP in 36
(48%), CVP in 1(1.3%), and Cytoxan in 1 (1.3%). Rituximabwas
administered to 63 (84%) as part of their pretransplant
regimen. Eight patients (11%) had evidence of MRD. Positive
MRD tests included: t(11:14) only in 4 (50%), ﬂow only in 2
(25%), and ﬂow and t(11;14) PCR positive in 2 (25%). Sites of
MRD included bone marrow in 5 (62.5%) and peripheral
blood in 4 (50%). MRD positivity was highly associated with
both OS and PFS in unadjusted and adjusted models (Figure
1). With a median follow-up of survivors of 5.1 years, the
median OS for MRD negative patients was not reached,
while for the MRD positive patients was 3.01 years (hazard
ratio [HR] 4.04, p ¼ 0.009). The median PFS for MRD
negative patients was not reached, while for the MRD
positive patients was 2.38 years (HR 3.69, p ¼ 0.002).
Discussion: These data indicate that MRD positivity is
independently associated with poor outcome following ASCT
for MCL patients despite achieving a clinical CR. New treat-
ment strategies such as post-transplant maintenance regi-
mens or reduced intensity allogeneic transplantation could
be evaluated in this setting in an attempt to improve
remission durations and survival.145
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Objective: To compare the outcome of patients with Non-
Hodgkins Lymphoma undergoing autologous peripheral
blood stem cell transplantation (PBSCT) conditioned with
FluBuTBI or BEAM (BCNU, Etoposide, Cytarabine, and
Melphalan) at our institution.
Patients and Methods: We conducted a retrospective anal-
ysis of patients (n¼81) who underwent autologous PBSCT at
our institution and were conditioned with BEAM (n¼40) or
FluBuTBI (n¼41) between January 2006 and January 2013.
Recipients were classiﬁed according to CIBMTR criteria and
those conditioned with BEAM were low risk (n¼14) and in-
termediate risk (n¼26). Recipients conditioned with Flu-
BuTBI were low risk (n¼10), intermediate risk (n¼27) and
high risk (n¼4). Median age of patients in the BEAM group
was 57.2 years compared to 59.6 years for FluBuTBI. At the
time of transplantation, 25 of 40 patients who received
BEAMwere in complete remission (62.5%) compared to 21 of
41 patients (51.2%) for FluBuTBI. Median time of follow up
was 57 months for BEAM and 30.2 months for FluBuTBI.FluBuTBI consisted of intravenous (IV) Fludarabine 50mg/
m2/day infused over 1 hour on days -6 through -2, IV
Busulfan 3.2 mg/kg/day on days -5 through -2 (infusion rate
80 mg/hour) and TBI 200 cGy on days -2 and -1. BEAM
regimen consisted of IV BCNU 300 mg/m2 infused over 1 hr
on day -5, Etoposide 200 mg/m2/day over 3 hours on days -5
through -2, Cytarabine 200 mg/m2/day over 1 hour every 12
hours on days -5 through -2, and Melphalan 140 mg/m2 over
1 hr on day -1. Diagnoses were transformed follicular lym-
phoma (n¼1), composite lymphoma (n¼1), CLL (n¼1),
anaplastic large cell lymphoma (n¼2), B-cell lymphoma NOS
(n¼3), Burkitt’s lymphoma (n¼3), peripheral T-cell lym-
phoma (n¼5), follicular lymphoma (n¼16), mantle cell
lymphoma (n¼23), diffuse large B-cell lymphoma (n¼ 26).
Results: Overall survival (OS) at 3 years for the FluBuTBI
group was 76.2% compared to BEAM at 57.5%. Cumulative
incidence of disease progression at 3 years was 24.5% for
FluBuTBI compared to 45% for BEAM group (p¼0.039).
Relapse related mortality (RRM) at 3 years for FluBUTBI was
8.7% compared to 32.4% for the BEAM group (p¼0.012).
Treatment related mortality was observed in 2.5% (n¼1) in
the BEAM group while none in the FluBuTBI group. Treat-
ment related MDS/AML occurred in 2.4% (n¼1) in FluBUTBI
compared to 7.5% (n¼3) in the BEAM group. Grade 3-4
mucositis was seen in 14.6% (n¼6) in the FluBuTBI group
while not observed in the BEAM group.
Conclusion: Our institutional data showed better OS and less
RRM in the FluBuTBI group compared to BEAM as condi-
tioning regimen for Non-Hodgkins Lymphoma undergoing
Autologous PSCT. This difference was present despite older
and higher risk patients in the FluBuTBI group. Mucositis was
more frequent in the FluBuTBI group. Conditioning with
FluBuTBI is a safe and effective alternative to BEAM for
autologous PBSCT which needs to be validated by random-
ized prospective studies.146
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Background: The use of plerixafor can decrease the number
of apheresis collection days for a given patient, which in turn
reduces cost and other various resources. An algorithm was
developed at our facility based on the paper published by LJ
Costa in 2010 to predict the need for plerixafor on day four of
G-CSF mobilization.
Methods: Peripheral blood is drawn on day four of G-CSF
mobilization (10mg/kg) for CD34 enumeration (pretube) us-
ing the single-platform ISHAGE method. If the value is <14
CD34/mL for a single transplant or <25 CD34/mL for a tandem
transplant the transplant recipient will receive plerixafor
(0.24mg/kg). If a patient does not qualify for plerixafor on the
day previous to apheresis and does not collect all CD34/kg
required on day one they receive plerixafor for day two of
apheresis. This algorithm is used for all autologous transplant
disease types treated at our facility (multiple myeloma, non-
Hodgkin lymphoma, Hodgkin lymphoma, and germ cell) and
is not adjusted for age, gender, performance status, etc.
except under the direction of the medical director. Our tar-
gets for stem cell collection are 3.0x106 CD34/kg for a single
transplant and 6.0x106 CD34/kg for tandem transplants.
Results: From 2007-2009 we had a total of 110 apheresis
collections (38 patients) for a single transplant with an
average of 2.5 collection days per patient using G-CSF alone.
23.7% (n¼9) of our patients collected in one day, 26.3%
